Swedish Orphan Biovitrum AB (SE:SOBI)
:SOBI
Top Page
Swedish Orphan Biovitrum AB
(SOBI)
Select Model
Select Model
Rating:64Neutral
Price Target:
kr424.00
▲(9.11% Upside)
Action:ReiteratedDate:02/07/26
The score is primarily supported by strong cash generation, solid operating profitability, and improving leverage, alongside a strong technical uptrend. It is held back by the sharp latest-year drop in net income/ROE and a very expensive valuation (P/E ~285), with overbought technical signals adding near-term risk.
Positive Factors
Free cash flow strength
Rebounding and robust free cash flow provides durable internal funding for R&D, commercialization of orphan therapies, debt reduction or partnerships. Strong FCF cushions the business through clinical cycles and supports long-term investment without requiring frequent external financing.
Negative Factors
Sharp net income / ROE drop
A sharp fall in net income and ROE signals deterioration in returns on capital that may reflect one-offs or persistent below-operating-line pressures. Sustained lower ROE weakens investment returns and could constrain capital allocation choices and investor confidence over months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow strength
Rebounding and robust free cash flow provides durable internal funding for R&D, commercialization of orphan therapies, debt reduction or partnerships. Strong FCF cushions the business through clinical cycles and supports long-term investment without requiring frequent external financing.
Read all positive factors
Swedish Orphan Biovitrum AB (SOBI) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr140.29B
Dividend YieldN/A
Average Volume (3M)396.16K
Price to Earnings (P/E)239.7
Beta (1Y)1.16
Revenue Growth9.50%
EPS Growth-99.31%
CountrySE
Employees1,895
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.39
Shares Outstanding357,412,840
10 Day Avg. Volume356,894
30 Day Avg. Volume396,160
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)3.04
Price to Sales (P/S)4.06
P/FCF Ratio13.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr481.67Price Target Upside23.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)17.06
Revenue Forecast (FY)kr31.58B
Swedish Orphan Biovitrum AB Business Overview & Revenue Model
Company Description
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America...
How the Company Makes Money
SOBI generates revenue primarily through the sale of its innovative biopharmaceutical products. The company has a diverse range of therapies, including those for hemophilia and rare inflammatory diseases, which are sold to healthcare providers and...
Swedish Orphan Biovitrum AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
79
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.24B | 26.03B | 22.12B | 18.79B | 15.53B |
| Gross Profit | 12.32B | 20.24B | 17.13B | 14.01B | 12.04B |
| EBITDA | 10.96B | 9.30B | 7.23B | 6.05B | 5.71B |
| Net Income | 478.00M | 3.88B | 2.41B | 2.64B | 2.68B |
Balance Sheet | |||||
| Total Assets | 67.43B | 75.44B | 74.03B | 52.50B | 48.66B |
| Cash, Cash Equivalents and Short-Term Investments | 1.04B | 1.14B | 904.00M | 1.36B | 1.04B |
| Total Debt | 11.75B | 16.73B | 20.48B | 9.10B | 10.91B |
| Total Liabilities | 29.71B | 35.15B | 40.16B | 25.97B | 25.46B |
| Stockholders Equity | 37.72B | 40.29B | 33.87B | 26.52B | 23.20B |
Cash Flow | |||||
| Free Cash Flow | 8.52B | 4.38B | -473.00M | 3.19B | 5.10B |
| Operating Cash Flow | 8.56B | 7.39B | 4.47B | 4.67B | 5.47B |
| Investing Cash Flow | -4.29B | -3.09B | -21.90B | -1.48B | -367.00M |
| Financing Cash Flow | -4.32B | -4.00B | 17.01B | -2.99B | -4.47B |
Swedish Orphan Biovitrum AB Technical Analysis
Positive
388.60
Price Trends
384.17
Positive
359.39
Positive
324.44
Positive
Market Momentum
5.06
Negative
61.84
Neutral
83.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Positive. The current price of 388.6 is above the 20-day moving average (MA) of 381.79, above the 50-day MA of 384.17, and above the 200-day MA of 324.44, indicating a bullish trend. The MACD of 5.06 indicates Negative momentum. The RSI at 61.84 is Neutral, neither overbought nor oversold. The STOCH value of 83.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SOBI.
Swedish Orphan Biovitrum AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | kr140.29B | 239.71 | 1.26% | ― | 9.50% | -99.31% | |
56 Neutral | kr629.54M | -60.92 | -48.65% | ― | -60.33% | 58.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr722.88M | -8.03 | ― | ― | -8.79% | -91.09% | |
47 Neutral | kr265.16M | -3.17 | -530.21% | ― | ― | 17.42% | |
44 Neutral | kr171.22M | -4.22 | -90.66% | ― | ― | 15.74% | |
41 Neutral | kr26.85M | -1.77 | ― | ― | ― | ― |
* Healthcare Sector Average
SE:SOBI
Swedish Orphan Biovitrum AB
406.80
156.20
62.33%
SE:ORX
Orexo AB
20.70
6.54
46.19%
SE:ALZCUR
AlzeCure Pharma AB
1.49
-0.88
-37.00%
SE:KLAR
Klaria Pharma Holding AB
1.08
-0.11
-8.95%
SE:NANEXA
Nanexa AB
3.83
2.68
232.61%
SE:ERMA
Enorama Pharma AB
0.36
-2.10
-85.37%
Swedish Orphan Biovitrum AB Corporate Events
Sobi Posts Strong 2025 Growth and Expands Rare Disease Portfolio With Strategic Deals and Launches
Feb 5, 2026
Sobi closed 2025 with strong operational momentum, reporting fourth-quarter revenue growth of 16% at constant exchange rates and an adjusted EBITA margin of 41%, driven mainly by a 25% haematology increase and robust demand for Altuvoct and Doptel...
Sobi Lifts 2025 Revenue and Profitability Above Previous Outlook
Jan 15, 2026
Sobi reported that its full-year 2025 revenue rose to approximately SEK 28.2 billion, equating to about 15% growth at constant exchange rates, with an adjusted EBITA margin of around 40%—both exceeding the company’s earlier guidance of...
Sobi Advances Gamifant After Positive Phase 2a Data in Interferon-Gamma–Driven Sepsis
Jan 7, 2026
Sobi announced that topline phase 2a data from the EMBRACE trial of Gamifant (emapalumab) in patients with interferon-gamma–driven sepsis (IDS) in Greece support proof of concept, showing improvements in organ dysfunction and survival when a...
Sobi Acquires Arthrosi Therapeutics to Strengthen Gout Treatment Pipeline
Dec 13, 2025
Swedish Orphan Biovitrum AB (Sobi) has announced its acquisition of Arthrosi Therapeutics, a biotechnology company specializing in next-generation treatments for gout. This strategic move enhances Sobi’s pipeline with pozdeutinurad, a promis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.